Minireviews
Copyright ©The Author(s) 2020.
World J Hepatol. Dec 27, 2020; 12(12): 1148-1157
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1148
Table 2 Integrative clinical-molecular subclassification of intrahepatic cholangiocarcinoma

Good prognostic subclass
Poor prognostic subclass
GSE26566Periductal infiltrating type, perineural invasion; KRAS mutation, EGFR and HER2 signatures
GSE32225Well differentiated tumor; inflammation-related signaturesPoor differentiated tumor; RTK-related pathways (AKT, MET, RAS/RAF/MAPK); overexpression of EGFR; KRAS mutation
GSE32879EMT-related signatures; TGFβ1, NCAM1, CD133
GSE89749Fluke-negative; FGFR fusion; BAP1, IDH mutationFluke-positive; BRCA1/2, TP53 mutation; ERBB2 gain
GSE107943Small duct type (cholangiolar type); underlying hepatitis, cirrhosis; metabolism-related signatures; FGFR2 fusionLarge duct type (bile duct type); Elevated CEA, CA 19-9; underlying cholangitis; P53, inflammation-related signatures; KRAS mutation
TCGA1Mitochondria/metabolic-related signatures; IDH, BAP1 mutationInflammation-related pathways